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Transient receptor potential melastatin 4Blood spinal cord barrier (BSCB) disruption after spinal cord injury (SCI) leads to secondary injury and results in
apoptosis of neurons and glia, leading to permanent neurological deﬁcits. Here, we examined the effect of ghrelin
on BSCB breakdown and hemorrhage after SCI. After moderate weight-drop contusion injury at T9 spinal cord,
ghrelin (80 μg/kg) was administered via intraperitoneal injection immediately after SCI and then the same
dose of ghrelin was treated every 6 h for 1 d. Our data showed that ghrelin treatment signiﬁcantly inhibited
the expression and activation ofmatrixmetalloprotease-9 (MMP-9) at 1 d after SCI. The increases of sulfonylurea
receptor 1 (SUR1) and transient receptor potential melastatin 4 (TrpM4) expressions at 1 h and 8 h after SCI re-
spectively were also alleviated by ghrelin treatment. In addition, both BSCB breakdown and hemorrhage at 1 d
after injury were signiﬁcantly attenuated by ghrelin. In parallel, the inﬁltration of blood cells such as neutrophils
and macrophages was inhibited by ghrelin treatment at 1 d and 5 d after SCI respectively. We also found that
ghrelin receptor, growth hormone secretagogue receptor-1a (GHS-R1a), was expressed in the blood vessel of
normal spinal tissue. Furthermore, the inhibitory effects of ghrelin on hemorrhage and BSCB disruption at 1 d
after SCI were blocked by GHS-R1a antagonist, [D-Lys-3]-GHRP-6 (3 mg/kg). Thus, these results indicate that
the neuroprotective effect by ghrelin after SCI is mediated in part by blocking BSCB disruption and hemorrhage
through the down-regulation of SUR1/TrpM4 and MMP-9, which is dependent on GHS-R1a.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Traumatic spinal cord injury (SCI) is a devastating condition that re-
sults in permanent disability. The blood–spinal cord barrier (BSCB) is
the functional equivalent of the blood–brain barrier (BBB) providing a
specialized microenvironment for the cellular constituents of the spinal
cord. When BSCB is damaged by injury, blood cells cross into injured
parenchyma and contribute to secondary injuries such as inﬂammation
[1–3]. These secondary damages induce apoptosis of neurons and glia,
leading to permanent neurological deﬁcits [4–6]. It has been well
known that the excessive expression and activation of matrixinal cord barrier; COX-2, cyclo-
tricoxidesynthase;i.p,intraper-
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khu.ac.kr (T.Y. Yune).metalloproteases (MMPs) can be detrimental, leading to numerous
pathological conditions including BBB or BSCB disruption after ischemic
brain injury and SCI [4,5,7,8]. Recently we reported that blocking BSCB
disruption after SCI by ﬂuoxetine or valproic acid (VPA) inhibits the
inﬁltration of blood cells followed inﬂammation, thereby reduces cell
death and improves functional recovery [9,10]. In addition, progressive
hemorrhage following necrotic cell death occurs at early stage after SCI,
which is known to be mediated by sulfonylurea receptor 1 (SUR1)-reg-
ulated Ca2+-activated, [ATP](i)-sensitive nonspeciﬁc cation (NC(Ca-
ATP)) channels [11] and de novo expression of transient receptor
potential M4 (TrpM4) [6]. The report by Simard et al. [12] also showed
that the suppression of Abcc8, which encodes SUR1, attenuates hemor-
rhagic necrosis of capillary endothelial cells following autodestruction
after SCI.
As a 28 amino-acid gastric hormone, ghrelin has been known to have
the neuroprotective effect in several animal models such as ischemia,
Parkinson's disease, Alzheimer's disease, and SCI [13–17]. In previous
our report, we showed that ghrelin treatment inhibits SCI-induced
apoptotic cell death and improves functional recovery, which ismediat-
ed through the ghrelin receptor, growth hormone secretagogue recep-
tor 1a (GHS-R1a) [14]. Ghrelin is also known to have binding capacity
at the endothelial cells of BBB [18]. Recently, it was reported that ghrelin
prevents BBB disruption after traumatic brain injury [19,20]. The report
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induced microvascular leak during inﬂammation.
Here we examined whether ghrelin prevents BSCB disruption and/
or hemorrhage and inhibits inﬂammation after SCI. As results, ghrelin
signiﬁcantly inhibited BSCB disruption and hemorrhage following the
inﬁltration of blood cells and inﬂammation by inhibiting the up-
regulation of SUR1/TrpM4 and MMP-9 expression and activation after
SCI, which were mediated through the GHS-R1a.
2. Materials & methods
2.1. Spinal cord injury
Adult rats [Sprague–Dawley; male; 250–300 g; n = 305; Sam:TacN
(SD) BR, Samtako, Osan, Korea] were anesthetized with chloral hydrate
(500 mg/kg) and a laminectomy was performed at the T9–T10 level
exposing the cord beneath without disrupting the dura. The spinous
processes of T8 and T11 were then clamped to stabilize the spine, and
the exposed dorsal surface of the cord was subjected to moderate
contusion injury (25 g-cm) using a New York University impactor as
previously described [14]. For the sham-operated controls, the animals
underwent a T10 laminectomywithoutweight-drop injury. Throughout
the surgical procedure, body temperature was maintained at 37 ±
0.5 °Cwith a heating pad. Postoperatively, rats received subcutaneously
supplemental ﬂuids (5 ml, lactated ringer) and antibiotics (gentamicin,
5 mg/kg, intramuscular injection) once daily for 5 d after surgery. The
bladder was emptied manually three times per day until reﬂexive
bladder emptying was established. All surgical interventions and post-
operative animal care were performed in accordance with the Guide-
lines and Polices for Rodent Survival Surgery provided by the Animal
Care Committee of the Kyung Hee University.
2.2. Drug administration
Acylated ghrelin (Peptides International, Louisville, KT) and an
antagonist to the ghrelin receptor, [D-Lys3]-GHRP-6 (Bachem, Torrance,
CA), were dissolved in sterile PBS. Rats were given with ghrelin
(80 μg/kg) via intraperitoneal (i.p.) injection immediately after SCI
and then the same dose of ghrelin was treated every 6 h for 1 d. To de-
termine the effect of delayed administration of ghrelin, ghrelin was also
injected at 1 h after SCI. [D-Lys3]-GHRP-6 (3 mg/kg, i.p.) was given at
30min before every ghrelin injection after injury. Since our previous re-
port showed that 80 μg/kg of ghrelin and 3 mg/kg of [D-Lys3]-GHRP-6
are an optimal dosage for neuroprotection after SCI [14], we used
these concentration of drugs throughout experiments. For the sham-
operated controls, rats underwent a T9–T10 laminectomy without
contusion injury, and received no pharmacological treatment. Vehicle-
control groups received equivolumetric i.p. injection of PBS at the corre-
sponding time points.
2.3. Evaluation of blood–spinal cord barrier permeability
The permeability of BSCB was investigated with Evans blue dye
extravasation according to previous reports [10,22] with some modiﬁ-
cations. Since our previous report showed that Evans blue dye extrava-
sation is signiﬁcantly increased at 1 d after SCI [10], we determined the
effect of ghrelin on BSCB permeability at 1 d after injury. At 1 d after SCI,
0.5ml of 2% Evans blue dye (Sigma, St. Louis, MO) solution in salinewas
administered (i.p.). Three hours later, rats were anesthetized and killed
by intra-cardiac perfusion with saline. The T9 spinal cord segment
(3 mm) was removed and homogenized in a 50% trichloroacetic acid
solution. Samples were centrifuged at 10,000 ×g for 10 min and super-
natants were collected. Then, its ﬂuorescence was quantiﬁed using a
spectrophotometer at an excitation wavelength of 620 nm and an
emission wavelength of 680 nm. Dye in samples was determined asmicrograms per gram of tissue from a standard curve plotted using
known amounts of dye.
2.4. Spectrophotometric assay of intraspinal hemorrhage
The hemoglobin content in the injured spinal cord tissue was quan-
tiﬁed with a spectrophotometric assay at 1 d as previously described
[12]. Rats were perfused with heparinized saline to remove intravascu-
lar blood, and5mmsegments of cord encompassing the lesion sitewere
homogenized and sonicated on icewith a pulse ultrasonicator for 1min.
After centrifugation at 16,000×g for 30min, the hemoglobin-containing
supernatant was collected and allowed to stand for 15 min. This reac-
tion converts hemoglobin to cyanomethemoglobin,which has an absor-
bance at 540 nm, and whose concentration can then be assessed by the
optical density of the solution at 550 nm. To validate whether the mea-
sured absorbance following these procedures reﬂects the amount of he-
moglobin, known quantities of bovine erythrocyte hemoglobin (Sigma)
were analyzedwith same procedures alongside every spinal cord tissue
assay. As an additional measure, bloodwas obtained from control rat by
cardiac puncture after anesthesia. Incremental aliquots of this blood
were then added to freshly homogenized spinal cord tissue obtained
from injured rats with or without ghrelin treatment to generate a stan-
dard absorbance curve.
2.5. Tissue preparation and immuohistochemistry
At speciﬁc time points after SCI, rats were anesthetized with chloral
hydrate and perfused via cardiac puncture initially with 0.1 M PBS and
subsequently with 4% paraformaldehyde in 0.1M PBS. A 20-mm section
of the spinal cord, centered at the lesion site, was dissected out, post-
ﬁxed by immersion in the same ﬁxative (4% paraformaldehyde) for 5
h and placed in 30% sucrose in 0.1 M PBS. The segment was embedded
in OCT for frozen sections, and longitudinal or transverse sections
were then cut at 10 or 20 μm on a cryostat (CM1850; Leica, Germany).
Frozen sections were processed for immunohistochemistry with anti-
bodies against myeloperoxidase (MPO, 1:100; Dako, Carpinteria, CA),
ED1 (1:200; Serotec, Raleigh, NC), GHS-R1a (1:300; Phoenix Pharma-
ceuticals Inc., Burlingame, CA), and RECA-1 (1:100; Santa Cruz Biotech-
nology, Santa Cruz, CA). For double labeling, FITC or cy3-conjugated
secondary antibodies were used (Jackson ImmunoResearch, West
Grove, PA). Also, nuclei were labeled with DAPI according to the
protocol of themanufacturer (Molecular Probes, Eugene, OR). Immuno-
staining control studies were performed by omission of the primary
antibodies, by replacement primary antibodies with non-immune,
control antibody, and by pre-absorption with an excess (10 μg/ml) of
the respective antigens. Serial sectionswere also stained for histological
analysis with Cresyl violet acetate. Since it has been known that neutro-
phils and macrophages were inﬁltrated at 1 d and 5 d after SCI respec-
tively [23], we determined the effect of ghrelin on the blood cells
inﬁltration into injured spinal cord by using MPO (neutrophils marker)
and ED-1 (macrophages marker) antibodies. For quantiﬁcation of MPO-
or ED-1-intensity, serial transverse sections (20 μm thickness) were
collected every 100 μm rostral and caudal 3000 μm to the lesion site
(total 60 sections). Digital images of MPO- or ED-1-stained tissues
were obtained and we quantiﬁed the ﬂuorescent intensity above
threshold by usingMetaMorph software (Molecular devices, Sunnyvale,
CA) and averaged. The threshold valuewas at least three times theback-
ground and the background was quantiﬁed and normalized to the
primary antibody omitted control.
2.6. Isolation of microvessels from spinal cord tissue
To isolate microvessels from spinal cord tissue, we used themethod
described previously [24]. The normal spinal tissue was minced and
homogenized in ice-cold PBS and then the homogenate was ﬁltered
through a 41 μm nylon mesh (Spectrum, Irving, TX). Microvessels
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pelleted by centrifugation at 4000 ×g for 10 min at 4 °C. The pellets
were resuspended in 15% dextran T-500 and then added onto 20%
dextran T-500, followed by centrifugation at 25,000 ×g for 10 min at
4 °C. The pellets were collected as the spinal cord microvessels and
stored at−80 °C until further analysis. The purity of the microvessels
preparation was veriﬁed and conﬁrmed by light microscopy.
2.7. RNA isolation and RT-PCR
RNA isolation using TRIZOL Reagent (Invitrogen, Carlsbad, CA) and
reverse transcripts were synthesized using the PrimeScript 1st strand
cDNA Synthesis Kit (Takara Bio, Shiga, Japan) from 1 μg of total RNA. A
20 μl PCR reaction contained 1 μl ﬁrst strand cDNA, 0.5 U taq polymerase
(Takara, Kyoto, Japan), 20 mM Tris–HCl, pH 7.9, 100 mM KCl, 1.5 mM
MgCl2, 250 μM dNTP, and 10 pmole of each speciﬁc primer. Samples
were subjected to 25–35 cycles of 95 °C 30 s, 50–65 °C 30 s, and 72 °C
for 30 s on a thermal cycler (Takara Bio). The primers used for tumor
necrosis factor (TNF)-α, interleukin (IL)-1β, cyclooxygenase-2 (COX-2),
inducible nitric oxide synthase (iNOS), MMP-2, MMP-9, Abcc8, TrpM4,
MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), Gro-α (CXCL1), MIP-2α
(CXCL2) and GAPDH were synthesized by the Genotech (Daejeon,
Korea) and the sequences of the primers are as follows (5′–3′): TNF-α for-
ward, 5′-CCCAGACCC TCACAC TCAGAT-3′; reverse, 5′-TTG TCC CTTGAA
GAG AAC CTG-3′ (55 °C, 25 cycles; 215 bp); IL-1β forward, 5′-GCA GCT
ACC TAT GTC TTG CCC GTG-3′, IL-1β reverse, 5′-GTC GTT GCT TGT CTC
TCC TTG TA-3′ (50 °C, 30 cycles; 289 bp): COX-2 forward, 5′-CCA TGT
CAA AAC CGT GGT GAA TG-3′; COX-2 reverse, 5′-ATG GGA GTT GGG
CAG TCA TCA G-3′ (55 °C, 28 cycles; 374 bp), iNOS forward, 5′-CTC CAT
GAC TCT CAG CAC AGA G-3′; iNOS reverse, 5′-GCA CCG AAG ATA TCC
TCA TGA T-3′ (56 °C, 25 cycles; 401 bp), MMP-2 forward, 5′-ACC ATC
GCC CAT CAT CAA GT-3′, MMP-2 reverse, 5′-CGA GCA AAA GCA TCA
TCC AC-3′ (55 °C for 35 cycles; 348 bp), MMP-9 forward, 5′-AAA GGT
CGC TCG GAT GGT TA-3′, MMP-9 reverse, 5′-AGG ATT GTC TAC TGG
AGT CGA-3′ (55 °C for 35 cycles; 698 bp), Abcc8 forward, 5′-CCT GCA
GCC AGA CAT AGA CA-3′, Abcc8 reverse, 5′-CAG TCA GCA TGA GGC
AGG TA-3′; (62 °C, 35 cycles; 276 bp), TrpM4 forward, 5′-CAG CGA CCT
CTA CTG GAA GG-3′, TrpM4 reverse, 5′-TCA CGA GCT TGT GCC AAT AG-
3′; (64 °C, 35 cycles; 258 bp); MCP-1 forward, 5′-TCA GCC AGA TGC
AGT TAA CG-3′, MCP-1 reverse, 5′-GAT CCT CTT GTA GCT CTC CAG C-3′,
(55 °C, 30 cycles; 125 bp), MIP-1α forward, 5′-ACT GCC TGC TGC TTC
TCC TAC A-3′, MIP-1α reverse, 5′-AGG AAA ATG ACA CCT GGC TGG-3′,
(60 °C, 35 cycles; 101 bp), MIP-1β forward, 5′-TCC CAC TTC CTG CTG
TTT CTC T-3′, MIP-1β reverse, 5′-GAA TAC CAC AGC TGG CTT GGA-3′,
(106 bp), Gro-α forward, 5′-CCG AAG TCA TAG CCA CAC TCA A-3′, Gro-
α reverse, 5′-GCA GTC GTC TCT TTC TCC GTT AC-3′, (63 °C, 35 cycles;
127 bp), MIP-2α forward, 5′-AGA CAG AAG TCA TAG CCA CTC TCA AG-
3′, MIP-2α reverse, 5′-CCT CCT TTC CAGGTC AGT TAG C-3′, (62 °C, 35 cy-
cles; 125 bp) and GAPDH forward, 5′-TCC CTC AAG ATT GTC AGC AA-3′;
GAPDH reverse, 5′-AGA TCC ACA ACG GAT ACA TT-3′ (50 °C, 23 cycles;
308 bp). After ampliﬁcation, PCR products were subjected to a 1.5 or 2%
agarose gel electrophoresis and visualized by ethidium bromide staining.
The relative density of bands (relative to shamvalue)was analyzed by the
AlphaImager software (Alpha Innotech Co.). RT-PCR analysis was
assessed at the indicated time points (e.g. Abcc8 at 1 h; TNF-α, IL-1β,
MCP-1, MIP-1β, MIP-2α at 2 h; COX-2, iNOS, MIP-1α, Gro-α at 6 h;
TrpM4 at 8 h, MMP-2, MMP-9 at 8 h and 1 d) based on our previous
reports [9,25]. Experiments were repeated three times and the values
obtained for the relative intensity were subjected to statistical analysis.
The gels shown inﬁgures are representative of results from three separate
experiments.
2.8. Western blot
Total proteinwas preparedwith a lysis buffer containing 1%Nonidet
P-40, 20 mM Tris, pH 8.0, 137 mM NaCl, 0.5 mM EDTA, 10% glycerol,10 mM Na2P2O7, 10 mM NaF, 1 μg/ml aprotinin, 10 μg/ml leupeptin,
1 mM sodium vanadate, and 1 mM phenylmethanesulfonylﬂuoride as
previously describe [10]. Tissue homogenates were incubated for
20 min at 4 °C, and centrifuged at 25,000 ×g for 30 min at 4 °C. The
protein concentration was determined using the BCA protein assay kit
(Pierce, Rockford, IL). Protein sample (50 μg) was separated on SDS-
PAGE gel electrophoresis and transferred to nitrocellulose membrane
(Millipore). The membranes were blocked in 5% non-fat skim milk or
5% bovine serum albumin in Tris-buffered saline containing tween-20
(0.1%) for 1 h at room temperature followed by incubation with anti-
bodies against, ED-1 (1:1000; Serotec), iNOS (1:1000; Transduction
Laboratory, Lexington, KY), COX-2 (1:1000; Cayman chemical, Ann,
Arbor, MI), ZO-1 (1:1000; Invitrogen), occludin (1:1000; Invitrogen),
SUR1 (1:1000; Santa Cruz Biotechnology), TrpM4 (1:1000; Santa Cruz
Biotechnology), and β-tubulin (1:30,000; Sigma). The primary antibody
was detected with a horseradish peroxidase-conjugated secondary
antibody (Jackson ImmunoResearch). Immunoreactive bands were vi-
sualized by chemiluminescence using Supersignal (Pierce). β-Tubulin
was used as an internal control. Western blot analysis was assessed at
the indicated time points (e.g. SUR1 at 1 h; ZO-1 at 4 h; TrpM4 at 8 h;
iNOS and COX-2 at 1 d; ED-1 and occludin at 5 d) based on previous
report [10].
2.9. Gelatin zymography
Since our previous report showed that MMP-9 activity is maximized
at 12–24h after SCI [9], we examined the activities ofMMP-2 andMMP-
9 at 1 d post-injury by gelatin zymography as described with some
modiﬁcations [10]. Total protein (50 μg) was loaded on a Novex 10%
zymogram gel (EC61752; Invitrogen) and separated by electrophoresis
with 100 V (19 mA) at 4 °C for 6 h. The gel was then incubated with
renaturing buffer (2.5% Triton X-100) at room temperature for 30 min
to restore the gelatinolytic activity of the proteins. After incubation
with developing buffer (50 mM Tris–HCl, pH 8.5, 0.2 M NaCl, 5 mM
CaCl2, 0.02% Brii35) at 37 °C for 24 h, the gel was stained with 0.5%
Coomassie blue for 24 h and then destainedwith 40%methanol contain-
ing 10% acetic acid until appropriate color contrast was achieved. Clear
bands on the zymogram were indicative of gelatinase activity. Relative
intensity of zymography (relative to sham or vehicle) was measured
and analyzed by AlphaImager software (Alpha Innotech Co.). Back-
ground was subtracted from the optical density measurements. Experi-
ments were repeated three times and the values obtained for the
relative intensity were subjected to statistical analysis.
2.10. Statistical analysis
Data presented as themean± SD values and hemorrhage and Evans
blue data are presented as the mean ± SEM. Comparisons between
vehicle and ghrelin treated groups were made by unpaired Student's t
test. Multiple comparisons between groups were performed one-way
ANOVA. Tukey's multiple comparison was used as Post hoc analysis.
Statistical signiﬁcance was accepted with p b 0.05. All statistical analy-
ses were performed by SPSS 15.0 (SPSS Science, Chicago, IL).
3. Results
3.1. Ghrelin inhibits SCI-inducedMMP-9 expression and activation after SCI
Recently we reported that excessive proteolytic activity of MMPs
such as MMP-2 and MMP-9 results in BSCB disruption after SCI [9,10].
Thus we ﬁrst examined the effect of ghrelin on the expression and
activation ofMMP-2 andMMP-9 after SCI. As shown in Fig. 1A, the levels
of MMP-2 and MMP-9 mRNA at 8 h and 1 d after injury were increased
as compared to shamcontrol. In addition, SCI-induced increase ofMMP-
9 mRNA expression was signiﬁcantly inhibited by ghrelin treatment as
compared to vehicle control, whereas MMP-2 mRNA expression was
Fig. 1.Ghrelin inhibits theMMP-9 expression and activation after SCI. Ratwas administrated immediatelywith ghrelin (80 μg/kg) after SCI and spinal cord tissueswere isolated at 8 h and
1 d after injury. RT-PCR (n=3) and gelatin zymography (n=4)were processed as described in theMaterials &methods section. (A) RT-PCR forMMP-2 andMMP-9. (B, C) Densitometric
analysis of RT-PCR. (D) Gelatin zymography at 1 d after injury. (E) Densitometric analysis of zymography. Note that ghrelin treatment signiﬁcantly inhibits MMP-9 expression and
activation after SCI. Data represent mean ± SD. *p b 0.05 vs. vehicle.
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and MMP-9 were also increased at 1 d after SCI (Fig. 1D) as reported
previously [4,26]. Furthermore, SCI-induced increase of MMP-9 activity
was signiﬁcantly inhibited by ghrelin as compared to vehicle control,
whereas MMP-2 activity was not, indicating ghrelin treatment inhibits
MMP-9 activity after SCI (Fig. 1E) (n = 4, MMP-9; Veh, 5.8 ± 0.31 vs.
Ghrelin, 2.3 ± 0.39, p b 0.05).
3.2. Ghrelin inhibits SUR1 and TrpM4 expression after SCI
It is known that both SUR1 and TrpM4 are up-regulated in the
endothelial cells of blood vessel after SCI andmediate progressive hem-
orrhagic necrosis [6,11]. To determine whether ghrelin inhibits SCI-
induced hemorrhage by SUR1/TrpM4,we examined the effect of ghrelin
on the SUR1/TrpM4 expression by RT-PCR and Western blot. After
injury, the levels of TrpM4 and Abcc8mRNAwere increased and peaked
at 1 h (in Abcc8) or 8 h (TrpM4) (Fig. 2A). In addition, SCI-induced
increases of Abcc8 and TrpM4 were signiﬁcantly inhibited by ghrelin
treatment after injury (Fig. 2B, C) (n = 3, Abcc8; Veh, 1.0 ± 0.08 vs.
ghrelin, 0.35 ± 0.03, TrpM4; Veh, 1.0 ± 0.07 vs. ghrelin, 0.29 ± 0.04,
p b 0.05). On the protein level, SUR1 and TrpM4 were increased and
peaked at 1 h (in SUR1) and 8 h (in TrpM4) after injury (Fig. 2D). In
particular, two forms of bands were detected in SUR1 (mature and
immature) and TrpM4 (core glycosylated, CG and highly glycosylated,
HG). Furthermore, ghrelin treatment signiﬁcantly inhibited SCI-
induced increases of SUR1 at 1 h and TrpM4 at 8 h after injury as
compared to vehicle controls (Fig. 2E, F) (n = 3, SUR1; Veh, 1.0 ±
0.04 vs. ghrelin, 0.35 ± 0.03, TrpM4; Veh, 1.0 ± 0.05 vs. ghrelin,
0.41 ± 0.06, p b 0.05).
3.3. Ghrelin inhibits BBB disruption and hemorrhage after SCI
Since our results showed that ghrelin inhibited MMP-9 activity and
SUR1/TrpM4 expression, we anticipated that ghrelin would attenuate
BSCB disruption and hemorrhage. As shown in Fig. 3A, the amount ofEvans blue dye extravasation was increased after SCI as compared to
sham control, indicating SCI elicits BSCB disruption. In addition, ghrelin
treatment after injury signiﬁcantly reduced the amount of Evans blue
dye extravasation when compared with vehicle control, indicating
ghrelin treatment attenuates BSCB disruption after SCI (Fig. 3B) (n =
5, Veh, 45± 2.6 vs. ghrelin, 21± 4.2, p b 0.05). Intraspinal hemorrhage
assay also showed that the amount of intraspinal blood increased after
injury was signiﬁcantly reduced by ghrelin treatment when compared
with vehicle control (Fig. 3C, D) (n = 5, Veh, 2.5 ± 0.2 vs. ghrelin,
1.25 ± 0.1, p b 0.05). In addition, we examined the effect of delayed
administration of ghrelin for clinical relevance. As shown in Supplemen-
tary Fig. 2A and B, both BSCB permeability and hemorrhage were signif-
icantly reduced by delayed ghrelin treatment (at 1 h after SCI) (n = 5,
Evans blue: Veh, 46 ± 1.8 vs. ghrelin, 25 ± 3.9; intraspinal blood: Veh,
2.7 ± 0.29 vs. ghrelin, 1.8 ± 0.22, p b 0.05).
It is known that the tight junction (TJ) in the endothelial cells of
blood vessel maintains the BBB integrity [2]. The loss or degradation of
TJ proteins is implicated to mediate the hyperpermeability of BSCB
after SCI [9,10]. Thus, we next examined the effect of ghrelin on the
level of ZO-1 and occludin in the injured spinal lysates by Western
blot. As shown in Fig. 3E–H, the decrease of the levels of ZO-1 at 4 h
and occludin at 5 d after SCI was signiﬁcantly attenuated by ghrelin
treatment as compared to vehicle control, indicating that ghrelin
prevents the loss of TJ proteins after injury (n = 4, ZO-1; Veh, 1.0 ±
0.07 vs. ghrelin, 1.8 ± 0.09, occludin; Veh, 1.0 ± 0.04 vs. ghrelin,
2.2 ± 0.11, p b 0.05).
3.4. Ghrelin inhibits the inﬁltration of neutrophils and macrophages after
SCI
It is known that the inﬁltration of blood cells such as neutrophils and
macrophages is followed by BSCB disruption and hemorrhage after SCI
[6,11,27]. Since ghrelin prevented BSCB disruption and hemorrhage
after SCI, we examined the effect of ghrelin treatment on the inﬁltration
of blood cells after injury. As shown in Fig. 4A, both MPO-positive
Fig. 2.Ghrelin inhibits SUR1 and TrpM4 expression after SCI. Spinal tissues treatedwith orwithout ghrelin (80 μg/kg; n=3)were prepared at indicated time points after injury. (A–C) RT-
PCR (upper) and densitometric analyses (bottom) of Abcc8 and TrpM4 mRNA. Note that both Abcc8 and TrpM4 mRNA were increased and peaked at 1 h and 8 h after SCI respectively,
which were signiﬁcantly inhibited by ghrelin treatment. Total protein from spinal cord tissues were prepared, and Western blot was performed as described in the Materials & methods
section. (D–F) Western blot (upper) and densitometric analyses (bottom) of TrpM4 and SUR1 protein were increased and peaked at 8 h and 1 h after SCI respectively. Note that ghrelin
treatment signiﬁcantly decreased the level of TrpM4 expression at 8 h and SUR1 expression at 1 h after injury when compared with than vehicle control. Data represent mean ± SD.
*p b 0.05 vs. vehicle.
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were observed in injured spinal cord. The analysis of relative ﬂuores-
cence intensity of the inﬁltrated blood cells showed that ghrelin
treatment signiﬁcantly inhibited the inﬁltration of neutrophils and
macrophages as compared to vehicle control (MPO: Veh, 1 ± 0.08 vs.
ghrelin, 0.36 ± 0.06; ED-1: Veh, 1 ± 0.05 vs. ghrelin, 0.36 ± 0.04;
n = 5, p b 0.05) (Fig. 4A, B). Western blot also showed that SCI-
induced increase of ED-1 level in injured spinal cord lysates was signif-
icantly decreased by ghrelin treatment at 5 d after injury as compared to
vehicle control (Fig. 4C) (n = 4, Veh, 1.0 ± 0.06 vs. ghrelin, 0.2 ±0.04,
p b 0.05).
3.5. Ghrelin inhibits the expression of inﬂammatory mediators after SCI
BSCB disruption and hemorrhage followed blood cell inﬁltration
after SCI are known tomediate inﬂammation and initiate the secondary
injury cascades [9,10,27]. Inﬁltrated cells produce inﬂammatory media-
tors such as IL-1β, TNF-α, COX-2 and iNOS [28]. In addition, the early
increase of chemokines such as Gro-α, MCP-1, MIP-1α, MIP-1β, and
MIP-2α after SCI is known to induce the inﬁltration of blood cells such
as neutrophils and macrophages, thereby facilitating inﬂammatory
responses [29–32]. Therefore, we postulated that the expression of
inﬂammatorymediators and chemokines would be inhibited by ghrelin
treatment after injury. By RT-PCR, the levels of TNF-α, IL-1β, iNOS and
COX-2 mRNA were increased after injury, which were signiﬁcantly
inhibited by ghrelin (n = 3) (Fig. 5A, B). The ghrelin treatment also
signiﬁcantly inhibited the levels of MCP-1, MIP-1α, Gro-α and MIP-2α
mRNA increased after injury (n = 3) (Fig. 5C, D). In addition, Westernblots showed that the protein levels of COX-2 and iNOS at 1 d after
injury were signiﬁcantly decreased by ghrelin as compared to vehicle
control (n = 4) (Fig. 5E, F).
3.6. Ghrelin receptor, GHS-R1a, is expressed in endothelial cell of blood
vessel in spinal cord
The endocrine activities of ghrelin are known to be mediated by
ghrelin receptor, GHS-R1a, a G protein protein-coupled receptor
expressedmainly in the pituitary and hypothalamus [33,34]. Previously
we reported that GHS-R1a is expressed in neuron and oligodendrocytes
in the spinal cord [14]. However, it is not known whether GHS-R1a is
expressed in the endothelial cell of blood vessel of spinal cord. Therefore
we examined whether GHS-R1a is expressed in the blood vessel of the
spinal cord. RT-PCR and in situ hybridization data revealed that GHS-
R1a mRNA was expressed in blood vessels isolated from normal spinal
cords (Fig. 6A, blood vessel, Supplementary Fig. 1D, arrowhead). Next,
to identifying the cell types expressing GHS-R1a except neuron and
oligodendrocyte, we performed double immunostaining with an anti-
body speciﬁc for the blood vessel, RECA-1. Double staining showed
that GHS-R1a was co-localized in the blood vessel (Fig. 6B).
3.7. The inhibitory effects of ghrelin on SCI-induced up-regulation of MMP-
9, SUR1, and TrpM4 is mediated via GHS-R1a
To examinewhether the inhibitory effects of ghrelin on SCI-induced
MMP-9, SUR1 andTrpM4 after SCIwould be dependent onGHS-R1a,we
used GHS-R1a antagonist, [D-Lys-3]-GHRP-6. Data showed that [D-Lys-
Fig. 3. Ghrelin alleviates BSCB disruption and hemorrhage after SCI. For measurement of
the BSCB permeability, 0.5 ml of 2% Evans blue dye was administered i.p. at 1 d after SCI
and 3 h later, spinal tissues were prepared for detection and quantiﬁcation of Evans blue
extravasation. (A) Representative whole spinal cords showing Evans blue dye perme-
abilized into the spinal cord at 1 d. (B) Quantiﬁcation of the Evans blue extravasation by
using ﬂuorometer (excitation at 620 nm and emission at 680 nm) (n = 5). Note that
Evans blue extravasation was signiﬁcantly reduced in ghrelin-treated rats as compared
with vehicle. The value was presented as an amount of dye (μg)/tissue weight (g). Data
represent as mean ± SEM. *p b 0.05 vs. vehicle. (C) Representative whole spinal cords
and spinal cord homogenates in e-tube. (D) Spectrophotometric quantiﬁcation of the
amount of blood in homogenates from vehicle and ghrelin-treated rats. Note that the
level of extravascular blood at 1 d after injurywas signiﬁcantly reduced in ghrelin-treated
rats as compared to vehicle (n= 5). Data represent mean± SEM. *p b 0.05 vs. vehicle. To
examine the degradation of TJ proteins after SCI, ratswere treatedwith ghrelin (80 μg/kg)
and total spinal extracts from injured spinal cord at indicated time points as described in
the Materials & methods section (n = 4). (E, G) Western blots of ZO-1 and occludin at
4 h and 5 d after injury respectively. (F, H) Densitometric analyses of Western blot. Data
represent mean ± SD. *p b 0.05 vs. vehicle.
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ghrelin on TrpM4 (at 8 h), Abcc8 (at 1 h) and MMP-9 (at 1 d) mRNA
expression after SCI (Fig. 7A, B). Western blots also showed that the
down-regulation of both TrpM4 (at 1 d) and SUR1 (at 1 h) expression
by ghrelin after injury was reversed by [D-Lys-3]-GHRP-6 treatment
(Fig. 7C, D) (Fig. 7C, n = 4, TrpM4: Veh, 1 ± 0.05; ghrelin, 0.43 ±
0.06; [D-Lys-3]-GHRP-6, 0.82 ± 0.06; SUR1: Fig. 7D, n = 4, Veh, 1 ±
0.05; ghrelin, 0.56 ± 0.06; [D-Lys-3]-GHRP-6, 0.77 ± 0.05, p b 0.05).
Furthermore, gelatin zymography also showed that [D-Lys-3]-GHRP-6
treatment abolished the inhibitory effect of ghrelin on MMP-9 activity
(Fig. 7E, F) (n = 4, MMP-9: Veh, 4.48 ± 0.5; ghrelin, 2.18 ± 0.3; [D-
Lys-3]-GHRP-6, 4.98 ± 0.4, p b 0.05).3.8. The inhibition of BSCB disruption/hemorrhage by ghrelin is mediated
through GHS-R1a
To conﬁrm that the inhibitory effects of ghrelin on SCI-induced up-
regulation of MMP-9, SUR1 and TrpM4 are dependent on GHS-R1a,
we next examined the effect of [D-Lys-3]-GHRP-6 on BSCB disruption
and hemorrhage at 1 d after injury. As shown in Fig. 8, the inhibition
of SCI-induced increases in the amount of Evans blue dye (Fig. 8A)
and blood by ghrelin (Fig. 8B) was signiﬁcantly reversed by [D-Lys-3]-
GHRP-6 treatment after injury (Fig. 8A, n = 5, Veh, 45.7 ± 3.5; ghrelin,
19 ± 3; [D-Lys-3]-GHRP-6, 38.2 ± 4, p b 0.05; Fig. 8B, n = 5, Veh, 2.5 ±
0.3; ghrelin, 1.4 ± 0.14; [D-Lys-3]-GHRP-6, 2.3 ± 0.21, p b 0.05).
4. Discussion
Our previous report showed that ghrelin treatment improves
functional recovery after SCI in part by inhibiting apoptosis of neurons
and oligodendrocytes [14]. However, the mechanisms underlying the
neuroprotective effect of ghrelin have not been fully understood. Here
this study showed that ghrelin treatment inhibits SCI-induced MMP-9,
SUR1, and TrpM4 expression and decreases SCI-induced MMP-9 activi-
ty, thereby attenuates BSCB disruption and SUR1/TrpM4-mediated
hemorrhage. The present study also demonstrated that the loss or
degradation of TJ proteins such as occludin and ZO-1 and the inﬁltration
of blood cells such as neutrophils and macrophages are signiﬁcantly
inhibited by ghrelin treatment after SCI. In addition, ghrelin treatment
inhibited the expression of inﬂammatory mediators such as COX-2
and iNOS and inﬂammatory cytokines and chemokines, thereby allevi-
ated inﬂammatory responses after SCI. Furthermore, we elucidated
that the inhibitory effects of ghrelin against BSCBdisruption and hemor-
rhage after SCI might bemediated via ghrelin receptor, GHS-R1a, which
is expressed in the blood vessel. Taken together, our results suggest that
the neuroprotective effect of ghrelin is mediated in part by inhibiting
the expression and activation of MMP-9, SUR1, and TrpM4, thereby
blocking BSCB disruption and hemorrhage followed blood cell inﬁltra-
tion after SCI.
It is known that the up-regulation of MMP-9 mediates BSCB disrup-
tion by degrading the basal components of TJ molecules, thereby facili-
tating the inﬁltration of immune cells and initiating SCI-induced
secondary damage [4]. Recently we showed that VPA and ﬂuoxetine
attenuates BSCB disruption by inhibiting MMP-9 induction and TJ
proteins degradation after SCI [9,10]. The report by Wang et al. [35]
also showed that VPA inhibits ischemia-induced BBB disruption and
brain edema by inhibiting MMP-9 induction and TJ breakdown. Thus,
blocking BSCB disruption by inhibiting excessive MMP activity can be
considered as a therapeutic target to reduce secondary damage after
SCI. In this study, we showed that ghrelin treatment signiﬁcantly
decreased the expression and gelatinase activity of MMP-9 at 1 d after
SCI (see Fig. 1), thereby attenuated BSCB disruption at 1 d (see Fig. 3A,
B), which is mediated through GHS-R1a (see Fig. 8A). TJ proteins are
essential components of BBB or BSCB and are known to be substrate of
MMP [36]. As shown in Fig. 3E–H, ghrelin treatment signiﬁcantly
inhibited the degradation of both ZO-1 and occludin at 4 h and 5 d
after SCI respectively. Furthermore, the report by Asahi et al. [8] showed
that transient focal cerebral ischemia-induced BBB disruption is attenu-
ated in MMP-9 knockout mice by reducing ZO-1 degradation as
compared to wild typemice. Thus, these results indicate that the inhibi-
tion of BSCB disruption by ghrelin might be mediated by inhibiting
MMP-9 activity and thereby reducing the degradation of TJ proteins
after SCI. Interestingly, our data showed that the expression and activity
of MMP-2 were not changed by ghrelin (see Fig. 1). We speculate that
this discrepancy may be resulted from different transcriptional regula-
tion of MMP-2 andMMP-9 and/or different timewindows for the effect
of ghrelin on MMP-2 and MMP-9. In our preliminary experiment, we
found a novel histone demethylase for MMP-9 gene transcription as
an epigenetic regulator. But this enzyme was not required for MMP-2
Fig. 4. Ghrelin attenuates neutrophils and macrophages inﬁltration after SCI. After SCI, ghrelin was treated and blood inﬁltration was assessed by measuring the ﬂuorescent intensity of
MPO or ED-1 immunoreactive area at 1 and 5 d or Western blot for ED-1 at 5 d after injury as described in the Materials & methods section (n = 4). (A) Representative photographs
at 2400 μm caudal to lesion epicenter showed MPO-labeled neutrophils or ED-1-labeled macrophages in the dorsal column of injured spinal tissues (cross section) injected with and
without ghrelin. Scale bar, 50 μm. (B) Relative ﬂuorescent intensity of MPO- and ED-1-positive cells. (C) Western blot (upper) and densitometric analysis (bottom) of ED-1 at 5 d after
injury. Note that ghrelin treatment signiﬁcantly inhibited the inﬁltration of blood cells after SCI when compared to vehicle control. Data represent mean ± SD. *p b 0.05 vs. vehicle.
Fig. 5.Ghrelin inhibits the expression of inﬂammatory factors after SCI. Total RNA andprotein extracts from vehicle or ghrelin-treated spinal cords at indicated time points after injurywere
prepared. (A, C) RT-PCR of IL-1β and TNF-α (at 2 h), COX-2 and iNOS (at 6 h), and chemokines (MCP-1, MIP-1β, and MIP-2α at 2 h; Gro-α and MIP-1α at 6 h) after injury (n = 3). (B,
D) Quantitative analyses of RT-PCR. (E) Western blots of iNOS and COX-2 at 1 d after injury. (F) Quantiﬁcation analysis of Western blot (n = 4). Data represent mean ± SD. *p b 0.05
vs. vehicle.
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Fig. 6.Ghrelin receptor, GHS-R1a, is expressed in endothelial cells of blood vessel in the spinal cord. Total mRNA and spinal tissues from normal spinal cord tissues were prepared, and RT-
PCR and immunoﬂuorescence staining were performed as described in theMaterials & method section (n= 3). (A) RT-PCR of GHS-R1a mRNA. (B) Representative photographs showing
that GHS-R1a was co-localized with RECA1-positive blood vessels in normal spinal cord tissue (upper panel) and isolated blood vessels (lower panel). Scale bar, 30 μm.
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ic regulation of MMP-9 and/or MMP-2 transcription. It has also been
reported that MMP-9 activity is increased by 12 to 24 h post-injury,
the time point that corresponds to maximal period of BSCB disruption.
However, MMP-2 activity is known to increase at delayed time (5–
7 d) after SCI, which then remains elevated for weeks. Some reports
showed that MMP-2 facilitates wound healing events and promotes
functional recovery after SCI [37,38]. Therefore, whether ghrelin isFig. 7. The inhibition of SCI-inducedMMP-9, SUR1, and TrpM4 expression by ghrelinwas reverse
was injected at 30min before ghrelin treatment after SCI and total lysates were prepared as des
1 h), andMMP-9mRNA (at 1 d) after injury. (B) Quantitative analyses of RT-PCR. (C)Western b
blots. (E) Zymography ofMMP-9 at 1 d after injury. Note that [D-Lys3]-GHRP-6 treatment signiﬁ
expression and activation. *p b 0.05 vs.; and #p b 0.05 vs. ghrelin-treated rats.involved in delayed activation of MMP-2 after SCI is needed as a future
study although ghrelin unaffected to theMMP-2 expression and activity
at early stage after SCI. Nevertheless, we can't rule out the possibility for
the involvement of MMP-2 in BSCB disruption after SCI.
It is known that a small hemorrhagic lesion near the lesion site is
observed at early stage (10–15min) after injury and then the petechial
hemorrhages (small spots of bleeding from capillaries) continue to form
and coalesce in more distant tissues rostrocaudally at 3–24 h, resultingdbyGHS-R1a antagonist treatment. TheGHS-R1a antagonist, [D-Lys3]-GHRP-6 (3 mg/kg),
cribed in theMaterials &methods section (n= 3). (A) RT-PCR of TrpM4 (at 8 h), Abcc8 (at
lots of TrpM4 (at 8 h) and SUR1 (at 1 h) after injury. (D) Quantitative analyses ofWestern
cantly attenuated the inhibitory effects of ghrelin on SCI-induced TrpM4, SUR1 andMMP-9
Fig. 8. GHS-R1a antagonist antagonizes the effects of ghrelin on SCI-induced BSCB disruption and hemorrhage. [D-Lys3]-GHRP-6 was injected at 30min before ghrelin treatment after SCI
and BSCB disruption and hemorrhage were assayed as described in the Materials & methods section (n= 5). (A) Quantiﬁcation of the Evans blue extravasation. (B) Spectrophotometric
quantiﬁcation of the amount of intraspinal blood in homogenates. Note that the inhibitory effects of ghrelin on BSCB disruption and hemorrhage were reversed by GSH-R1a antagonist.
Data represent as mean ± SEM. *p b 0.05 vs. vehicle; and #p b 0.05 vs. ghrelin treated rats.
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molecular mechanisms underlying progressive hemorrhagic necrosis,
which is mediated via SCI-induced SUR1 and TrpM4 expression in
the capillary endothelium [6,11,12]. In this study, SUR1 and TrpM4
were strongly up-regulated at 1 h and 8 h after SCI respectively and
ghrelin treatment signiﬁcantly inhibited the up-regulation of SUR1
and TrpM4, thereby hemorrhage was signiﬁcantly attenuated by
ghrelin. Furthermore, the hemorrhage was also inhibited by delayed
administration of ghrelin (1 h after SCI) (Supplementary Fig. 2).
These results suggest that the neuroprotective effect of ghrelin is in
part mediated by inhibiting progressive hemorrhage after SCI. In
addition, we found that anti-hemorrhagic effect of ghrelin wasmedi-
ated by GSH-R1a, which is expressed in the capillary endothelium.
However, how GHS-R1a mediated signaling by ghrelin inhibits
SUR1 and TrpM4 expression was not examined in this study. Thus,
the study for this mechanism is needed as a future study.
Our study also showed that ghrelin treatment signiﬁcantly inhibited
the expression of inﬂammatory mediators (iNOS and COX-2 at 1 d),
cytokines (TNF-α and IL-1β at 2 h) and chemokines (MCP-1 and MIP-
2α at 2 h; Gro-α and MIP-1α at 6 h) (see Fig. 5). It is well known that
inﬂammatory cells such as neutrophils and macrophages inﬁltrated
via BSCB disruption and hemorrhage produce inﬂammatory factors,
thereby increase tissue damage, induce apoptotic cell death, and impair
functional recovery after SCI [41–43]. Several studies also demonstrated
that suppression of neutrophils and macrophages inﬁltration after
injury ameliorates apoptotic cell death and improves functional recov-
ery [44–46]. Thus, our results suggest that the neuroprotective effect
of ghrelin might be mediated by inhibiting BSCB disruption and hemor-
rhage followed inﬂammation by the inﬁltrated blood cells.
It is reported that ghrelin transiently decreases the blood pressure by
suppressing sympathetic nerve activity. For example, the report by
Freeman et al., [47] showed that intracerebroventricular infusion of
ghrelin reduces the blood pressure by causing reduction in sympathetic
nerve activity in normal rat. In addition, systemic administration of
ghrelin signiﬁcantly reduced the blood pressure in healthy volunteers
[48]. When we determined the effect of ghrelin on blood pressure in
this study, the arterial pressure was not different between ghrelin-
and vehicle-treated rats after SCI although ghrelin treatment transiently
reduced arterial pressure in normal rat (data not shown). Based on our
data, we speculate that the blood pressure may not inﬂuence on the
anti-hemorrhagic effect of ghrelin in SCI-induced pathological condi-
tion. However, we cannot rule out the possibility for the involvement
of ghrelin in hemorrhage by suppressing sympathetic nerve activity
after SCI.
In summary, our data show that the neuroprotective effect of ghrelin
is mediated in part by inhibiting the up-regulation of SUR1, TrpM4, andMMP-9 and thereby attenuating BSCB disruption and hemorrhage
followed blood cell inﬁltration after SCI. Furthermore, the present
study suggests that ghrelin can be potentially useful as a therapeutic
agent for traumatic injury including SCI accompanying with BBB/BSCB
disruption and hemorrhage.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.09.006.
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